The current approach to approving new medicines often lowers the threshold for access, allowing patients to receive treatments without solid evidence of their effectiveness or safety. This situation risks exposing individuals to potentially ineffective or harmful drugs, as decisions are increasingly influenced by anecdotes rather than rigorous data. Such trends underscore the need for critical examination of drug approval processes.
With rapid advancements in biotechnology introducing entirely new classes of treatments, the stakes have never been higher. The core ethical and practical questions concern who should determine eligibility for experimental therapies and how to balance access with patient safety and evidence-based practice. Addressing these challenges is essential to ensure that medical innovation benefits patients without unnecessary risks or exploitation.
Failure to carefully regulate access could lead to widespread use of ineffective treatments and undermine trust in biomedical research and healthcare systems. Ongoing dialogue and policy refinement are required to navigate the complex landscape of emerging therapies responsibly.
👉 Pročitaj original: MIT Technology Review
